Patent 11007142 was granted and assigned to Albireo AB on May, 2021 by the United States Patent and Trademark Office.
The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.